If there is one piece of information about ovarian cancer that every woman deserves to know, it’s this: there is currently no reliable routine screening test for ovarian cancer in women at average risk. No Pap smear equivalent. No blood test that functions dependably as an early detection tool for the general population. This single fact has profound implications for how women think about their risk, recognize symptoms, and engage with their gynecologic care. At Ovation OB/GYN in Frisco, Texas, we believe that understanding this truth, fully and clearly, is the first step toward taking it seriously.
“The doctor was so sweet and made me feel heard. She explained everything in a positive manner. I would definitely recommend Dr. Laura Bradley to others.”
-Ovation OB/GYN Patient Testimonial
Why the Absence of Screening Matters So Much
Ovarian cancer is the fifth leading cause of cancer-related death among women in the United States, and it carries a disproportionately high mortality rate compared to other gynecologic cancers. The primary reason is not that it is inherently more aggressive than other cancers; it’s that it is so frequently diagnosed at an advanced stage. When ovarian cancer is caught at Stage I, confined to the ovary, the five-year survival rate exceeds 90 percent. By Stage IV, when the cancer has spread to distant organs, that rate drops below 30 percent.
The gap between those outcomes is largely explained by the absence of effective early detection. Cervical cancer’s mortality rate has plummeted over the past several decades precisely because Pap smears can catch precancerous changes before cancer develops. No equivalent tool exists for the ovaries and until one does, women’s best protection is a clear-eyed understanding of what that means for how they monitor their own health.
What Has Been Tried and Why It Hasn’t Worked
The search for an effective ovarian cancer screening tool has been ongoing for decades. Two approaches have received the most clinical attention: transvaginal ultrasound, which visualizes the ovaries and can detect structural abnormalities, and CA-125, a protein that is often elevated in women with ovarian cancer.
Unfortunately, neither has proven effective as a general population screening tool. Transvaginal ultrasound produces too many false positives; findings that look abnormal but are not cancerous, leading to unnecessary surgeries and procedures. CA-125 is even more limited: it is elevated in only about half of early-stage ovarian cancers, and it can be elevated for entirely benign reasons including endometriosis, uterine fibroids, and even menstruation. Large, well-designed clinical trials of both approaches in average-risk women have not demonstrated a reduction in ovarian cancer mortality.
This does not mean these tools have no role. For women at high risk due to BRCA1 or BRCA2 mutations, Lynch syndrome, or a strong family history of ovarian or breast cancer, enhanced surveillance using transvaginal ultrasound and CA-125 is often recommended, typically in combination and at regular intervals. The goal is not perfect detection but rather meaningful risk monitoring for those whose baseline risk justifies it.
The Role of Symptoms
Because screening is not available for average-risk women, symptom recognition becomes one of the most important tools available. The challenge is that ovarian cancer’s symptoms are nonspecific; meaning they overlap significantly with common, benign conditions. Bloating, pelvic or abdominal discomfort, difficulty eating or feeling full quickly, and urinary urgency or frequency are the most consistently reported early symptoms. Back pain, fatigue, and changes in bowel habits may also occur.
What distinguishes ovarian cancer symptoms from routine digestive or bladder complaints is their persistence and their clustering. When multiple symptoms occur together, they are new or unexplained, and they persist for more than two to three weeks, they warrant evaluation; not reassurance and watchful waiting. Women who are attuned to their bodies and who report changes promptly to their provider give themselves the best possible chance at earlier detection.
Genetic Risk and What to Do About It
Approximately 10 to 15 percent of ovarian cancers are linked to hereditary mutations, most commonly in the BRCA1 or BRCA2 genes. Women with a BRCA1 mutation face a lifetime ovarian cancer risk estimated between 35 and 70 percent; for BRCA2, the range is typically 10 to 30 percent. Lynch syndrome, a hereditary condition affecting DNA repair, also confers significantly elevated risk.
If you have an immediate relative: a parent, sibling, or child with ovarian or breast cancer, or if multiple relatives on the same side of your family have been diagnosed, genetic counseling is worth pursuing. A positive genetic test result doesn’t mean cancer is inevitable, but it does unlock a range of proactive options: more intensive surveillance, chemoprevention discussions, and, for women who have completed childbearing, risk-reducing salpingo-oophorectomy, which can reduce ovarian cancer risk by more than 80 percent in high-risk women.
“Celynne was professional, helpful and kind. She answered my questions and explained what was happening.”
-Ovation OB/GYN Patient Testimonial
What Routine Care Still Provides
While a dedicated ovarian cancer screening test doesn’t exist, regular well women care appointments still matter. Annual pelvic exams allow your provider to assess the ovaries and surrounding structures, though they cannot reliably detect early-stage ovarian cancer. These visits are also when you can discuss any new or persistent symptoms, review your family history, and ensure that your overall gynecologic health is monitored. Our comprehensive services include the full range of preventive gynecologic care, including Pap smears and breast cancer screening, as part of a complete approach to women’s health.
The absence of an ovarian cancer screening test is not a reason for fatalism; it’s a reason for vigilance, informed self-awareness, and a strong relationship with a gynecologic provider you trust. Request an appointment with Ovation OB/GYN in Frisco, Texas, or call us at (972) 777-3232 to schedule your next visit.